Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...
Hosted on MSN
Google techie confesses to lacking basic coding skills. Man tags CEO Sundar Pichai: ‘Is this guy serious?’
A LinkedIn post of a Google software engineer sparked a debate after he admitted to not understanding several fundamental software engineering concepts. His list of unfamiliar topics included ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback